Adam Elnaggar
Gynecologic Oncology · Germantown, TNNPI 1194954222
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,524 of the $29,365 with a category attached, or 83.5%. 27 manufacturers reported payments, led by AstraZeneca at 32.5% of the total. Reporting peaked in 2020 at $12,376 and has fallen 99.8% since, to $23 in 2025. Among gynecologic oncology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $264.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Merck$9K
- GSK$4K
- AbbVie$2K
- Eisai Inc.$2K
- Clovis Oncology, Inc.$793
- plus $2K from 21 others
Across 157 payments — averaging $5972.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$466K
- GSK$300K
- AstraZeneca$99K
- EMD Serono, Inc.$61K
- Astrazeneca UK Limited$12K
What the payments were for
- Consulting fees$24,52484%
- Travel & lodging$1,1234%
- Food & beverage$3,65812%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $9,547 |
| Merck | 20 | $8,837 |
| GSK | 6 | $3,730 |
| AbbVie | 4 | $2,479 |
| Eisai Inc. | 2 | $2,464 |
| Clovis Oncology, Inc. | 15 | $793 |
| Johnson & Johnson(2 entities) | 9 | $479 |
| Seagen Inc. | 5 | $243 |
| Medtronic | 1 | $138 |
| Myriad Genetic Laboratories, Inc. | 1 | $115 |
| Intuitive Surgical | 2 | $112 |
| Tesaro, Inc. | 3 | $96 |
| Astrazeneca UK Limited | 1 | $80 |
| Beigene USA, Inc. | 2 | $33 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Foundation Medicine, Inc. | 2 | $26 |
| Bayer | 2 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Tersera Therapeutics LLC | 1 | $12 |
| Verastem, Inc. | 1 | $11 |
| Bristol Myers Squibb | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$9,048
- LENVIMA$2,464
- ZEJULA$1,300
- Rubraca$227
- Avalus$138
- ENSEAL Product Family$125
- VISTASEAL Fibrin Sealant (Human)$117
- myChoice CDx$115
How this compares
$29,365 in reported general payments places this provider in the 90th percentile of 40 gynecologic oncology providers in Tennessee.
Other gynecologic oncology in Germantown
- Todd TillmannsGermantown$127K
- Michael UlmGermantown$7K
- Linda SmileyGermantown$6K
- Mark ReedGermantown$4K
- Laura HarbinGermantown$2K
- Ronald AlvarezNashville$33K
- Michael StanyNashville$13K
- Dennis DesimoneKingsport$9K
- John SchorgeMemphis$8K
- Thomas NumnumNashville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.